【禾榮科】本公司研發之B10 L-BPA 注射液向台灣衛生福利部食品藥物 管理署(TFDA)提出術前輔助治療局部晚期口腔癌之學術研究用人 體臨床試驗審查申請(IND)
NQ 評分
0/100
N1 內容完整性
0
AI 摘要（NQ 加工版）
Heroic has submitted an Investigational New Drug (IND) application to Taiwan's TFDA for its B10 L-BPA injection, aimed at pre-operative adjuvant therapy for locally advanced oral cancer. This study will evaluate Boron Neutron Capture Therapy (BNCT) as a novel treatment strategy.